Your doctor may give you medicine before each infusion to decrease your chance of side effects. Your doctor may stop your treatment, delay your treatment, or change your dose of ZYNLONTA® if you have severe side effects.
Your doctor should do blood tests regularly to check for side effects of ZYNLONTA®. Your doctor will decide how many treatments you need.
ZYNLONTA® is a prescription treatment for adults who have certain types of diffuse large B-cell lymphoma (or DLBCL) after 2 or more treatments did not work.
ZYNLONTA® is a targeted therapy that attaches to cancer cells and releases cancer-killing treatment. It is NOT traditional chemotherapy. It is what’s known as an antibody-drug conjugate (or ADC). There are different ADCs that can target different types of cancer cells. ZYNLONTA® is an ADC that targets the cancer cells of DLBCL.
The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.
Learn more: How ZYNLONTA® Targets Cancer
ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, and who have already received 2 or more treatments for their cancer.
It is not known if ZYNLONTA® is safe and effective in children.
The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.
Learn more: Get Results for ZYNLONTA®
Yes. The ZYNLONTA® clinical trial included people with relapsed/refractory DLBCL who had already received a variety of therapies, including:
- Chemotherapy
- RITUXAN® (rituximab)
- CAR-T therapy
- Stem cell transplant
Talk with your doctor about your specific case and treatment history.
Learn more: Get Results for ZYNLONTA®
About 48% of people saw results with ZYNLONTA®.
- Nearly 24% had all signs of the cancer go away (a “complete response”)
- That’s 35 out of 145 people
- Nearly 24% had some of the cancer lessen (a “partial response”)
- That’s 35 out of 145 people
Nearly 50% of patients saw a response in 1.3 months or 2 treatments.
- This is called the “median time.” That means it took half of people 1.3 months to have a response. And it took the other half longer to respond, up to 8.1 months. The range of response was between 1.1 months and 8.1 months.
Nearly 50% of patients saw their results last for about 10.3 months.
- This is called the “median duration of response.” That means half of people’s cancer kept on responding to treatment without it growing or spreading for 10.3 months.
- “Median duration of response” means that one half of people responded for a shorter amount of time, and the other half responded for a longer amount of time.
Learn more: Get Results for ZYNLONTA®
Relapse means previous therapies may have worked, but the cancer has come back at least once. Refractory means the cancer has not responded to past therapy/therapies.
Learn more: Discussions With Your Doctor
A partial response means signs of cancer have been reduced. Complete response means signs of cancer have disappeared. This does not always mean the cancer has been cured. Overall response includes both complete responses and partial responses.
Learn more: Find Results for ZYNLONTA®
About 50% of patients saw a response in 1.3 months. It took the other half longer to respond, up to 8.1 months. The range of response was between 1.1 months and 8.1 months.*
*In a clinical trial, 145 patients with DLBCL that has come back (relapsed) or did not respond to previous treatment (refractory) were treated with ZYNLONTA® to see how well it worked. The median time that it took for half of people to respond was 1.3 months. It took the other half longer to respond, up to 8.1 months.
Learn more: Find Results for ZYNLONTA®
During treatment with ZYNLONTA®, your doctor will monitor your blood counts and run other laboratory tests through blood samples. Ask your doctor’s office to learn how often this testing will be required.
You will be monitored for infusion site reactions, infections, and skin reactions. You may also need CT scans to monitor the DLBCL.
Learn more: About ZYNLONTA® Infusions
If you miss a ZYNLONTA® treatment, be sure to alert your doctor immediately to discuss your options.
Learn more: Discussions With Your Doctor
This may depend on your routine and how you do with treatment. Talk to your doctor’s office for more information.
Learn more: Discussions With Your Doctor
Avoid or limit your exposure to sunlight, including sunlight through glass, such as buildings or vehicle windows, and artificial sunlight, such as sunlamps or tanning beds. Exposure to sunlight during treatment with ZYNLONTA® can cause skin reaction or rash. Use sun-protection measures such as sunscreen and wear loose-fitting clothes that cover your skin while out in sunlight.
Learn more: Possible Side Effects
Before you receive ZYNLONTA®, tell your doctor about all of your medical conditions, including if you:
- have an active infection or have had one recently
- have liver problems
- are pregnant or plan to become pregnant. ZYNLONTA® can harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if ZYNLONTA® passes into breast milk. Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®
Tell your doctor and their office about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get new medicine.
Consult with your doctor to determine if ZYNLONTA® is right for you.
Learn more: Possible Side Effects
You should not try to become pregnant on ZYNLONTA®. Tell your doctor right away if you become pregnant or think that you are pregnant during treatment with ZYNLONTA®. Your doctor may do a pregnancy test before starting treatment with ZYNLONTA®.
You should use effective birth control (contraception) during treatment with ZYNLONTA® and for 10 months after the last dose of ZYNLONTA®. Talk to your doctor about effective birth control. Males with female partners who can become pregnant should use effective birth control during treatment with ZYNLONTA® and for 7 months after the last dose of ZYNLONTA®.
If you are pregnant or may become pregnant, consult your doctor before starting ZYNLONTA®.
Learn more: Possible Side Effects
Do not breastfeed during treatment with ZYNLONTA® and for 3 months after the last dose of ZYNLONTA®.
If you are breastfeeding, consult your doctor regarding ZYNLONTA®.
Learn more: Possible Side Effects
ZYNLONTA® may cause fertility problems in males, which may affect your ability to have children. Talk to your doctor if this is a concern for you.
Learn more: Possible Side Effects
Your doctor or doctor’s office will prescribe ZYNLONTA® in a dose that is right for you.
ZYNLONTA® is given by an intravenous (IV) infusion at a clinic or infusion center.
- You will receive an infusion once every 3 weeks
- Each infusion will last about 30 minutes
- Your doctor may give you medicine before each infusion to lower your chance of side effects
- Your doctor may stop your treatment, delay your treatment, or change your dose of ZYNLONTA® if you have serious side effects
- You will be monitored for infusion site reactions, infections, and skin reactions
- Your doctor will decide how many treatments you need
Learn more: About ZYNLONTA® Infusions
Before every ZYNLONTA® treatment, you may be given a prescription steroid to take 2 times a day for 3 days, starting the day before your infusion. Your doctor will determine if this is appropriate for you and may choose to give you the steroid as an oral medication or IV infusion.
Learn more: About ZYNLONTA® Infusions
The infusion of ZYNLONTA® takes about 30 minutes.
Learn more: About ZYNLONTA® Infusions
ZYNLONTA® may cause serious side effects, including:
- Fluid retention: Your body may hold too much fluid during treatment with ZYNLONTA®. This can be serious. Tell your doctor’s office if you experience new or worsening swelling or puffiness, weight gain, chest pain, shortness of breath, or difficult, labored breathing
- Low blood cell counts: (platelets, red blood cells, and white blood cells): Low blood cell counts are common with ZYNLONTA® but can also be serious or severe. Your doctor’s office will monitor your blood counts during treatment with ZYNLONTA®. Tell your doctor right away if you get a fever of 100.4°F (38°C) or above, or if you have any bruising or bleeding
- Infections: Serious infections, including infections that can cause death, have happened in people treated with ZYNLONTA®. Tell your doctor’s office right away if you have new or worsening signs or symptoms of infection, including fever, chills, flu-like symptoms (cough, tiredness or weakness, and body aches), headache, breathing problems, or cuts or scrapes that are red, warm, swollen or painful
- Skin Reactions: Serious skin reactions have happened in people treated with ZYNLONTA®. Tell your doctor’s office if you get new or worsening skin reactions, including sensitivity to sunlight, skin rash, peeling, redness or irritation. You may burn more easily or get severe sunburns
Get in touch with your doctor’s office if you see any signs of serious side effects. It may be important.
If you have a serious side effect, your doctor will explain how it will be managed.
Your doctor may stop your treatment, delay your treatment, or change your dose of ZYNLONTA® if you have serious side effects.
For more information on serious side effects, read the Important Safety Information.
The first place to find support is with your doctor and doctor’s office. There are also resources available from ADC Therapeutics, the maker of ZYNLONTA®, through the ADVANCING Patient Support Program.
To learn more about personalized assistance and support available through ADVANCING Patient Support, visit ADVANCINGPatientSupport.com or call 1-855-690-0340.
Additional support is available through the Lymphoma Research Foundation and the Leukemia & Lymphoma Society®.
Learn more: Savings, Support & Resources
ADVANCING Patient Support offers patients personalized assistance from ADC Therapeutics. Your personal case manager will be trained on your specific case, so they can provide you with the help and support you need.
Visit ADVANCINGPatientSupport.com to learn more.
The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.
Learn more: Savings, Support & Resources
Along with our website, check out the information from these organizations:
Learn more: Savings, Support & Resources
Your doctor’s office may be able to help you enroll in ADVANCING Patient Support if you are currently taking ZYNLONTA®.
Learn more: Savings, Support & Resources
The Lymphoma Research Foundation is a one-to-one peer support program for people with lymphoma and those who care for them. The Leukemia & Lymphoma Society® may also be able to match you up with support groups in your area.
